Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Inhibikase Therapeutics Inc
IKT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.62
-0.025
-1.52%
Últ. Act.: Oct 19, 7:25 PM
$1.62
-0.025
-1.52%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
Inhibikase Therapeutics Financials
Inhibikase Therapeutics (IKT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share
Benzinga Newsdesk
PRO
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share
Benzinga Newsdesk
PRO
Inhibikase Therapeutics Q3 EPS $(0.13), Inline
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 80 percent increase over losses of $(0.65) per share from the same period last year.
Benzinga Newsdesk
PRO
Inhibikase Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 83.33 percent increase over losses of $(0.66) per
Benzinga Newsdesk
PRO
Inhibikase Therapeutics Q1 EPS $(0.15) Misses $(0.12) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share
Benzinga Newsdesk
